

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-16 (Cancelled)

17. (Currently Amended) An expression system comprising:

an isolated recombinant host cell comprising:

a first expressible recombinant polynucleotide which encodes

a human core 1  $\beta$ 3-galactosyl transferase which  
~~requires coexpression of a core 1  $\beta$ 3-galactosyl~~  
~~transferase specific molecular chaperone for~~  
~~configuring the core 1  $\beta$ 3-galactosyl transferase in an~~  
~~active form; and~~

a second expressible recombinant polynucleotide which  
encodes ~~the a~~ human core 1  $\beta$ 3-galactosyl transferase  
specific molecular chaperone for expressing the active  
form of the human core 1  $\beta$ 3-galactosyl transferase,  
wherein the second expressible recombinant  
polynucleotide comprises:

- (A) a polynucleotide having the sequence SEQ ID NO.: 2;
- (B) ~~a polynucleotide which hybridizes with the polynucleotide~~  
~~having the sequence SEQ ID NO: 2 under stringency~~

conditions comprising prehybridization and hybridization at 68°C followed by washing twice with 0.1 x SSC, 0.1% SDS for 20 minutes at 22°C, and washing twice with 0.1 x SSC, 0.1% SDS for 20 minutes at 50°C; or prehybridization and hybridization at 42°C in 5 x SSPE, 0.3% SDS, 200 ug/ml sheared and denatured salmon sperm DNA, and 50% formamide, and washing with 2 x SSC, 0.2% SDS at 65°C;

(C) (B) a polynucleotide which differs in nucleotide sequence from the polynucleotide of (A) due to the degeneracy of the genetic code and which encodes a protein having human core 1  $\beta$ 3 galactosyl transferase specific molecular chaperone activity protein; or

(D) (C) a polynucleotide which differs in nucleotide sequence from the polynucleotides of (A), or (B) or (C) in that said polynucleotide lacks a nucleotide sequence which encodes a transmembrane domain wherein the encoded human core 1  $\beta$ 3 galactosyl transferase specific molecular chaperone is soluble.

18. (Currently Amended) The expression system of claim 17 wherein the second expressible ~~recombinant~~ recombinant polynucleotide comprises the sequence of SEQ ID NO: 2.

19-23. (Cancelled)

24. (Currently Amended) The expression system of claim 17 wherein the first expressible ~~recombinant~~ polynucleotide and the second expressible recombinant polynucleotide are operatively associated with an expression control sequence.

25. (Previously Presented) The expression system of claim 17 wherein the recombinant host cell further comprises an expressible polynucleotide encoding a peptide or polypeptide requiring post-translational glycosylation to form a core 1 structure.

26. (Previously Presented) The expression system of claim 25 wherein the peptide or polypeptide requiring post-translational glycosylation to form a core 1 structure comprises P-selectin glycoprotein ligand-1 or a portion thereof which has P-selectin binding activity.